Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A

Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Discussion Session

Time: Monday June 3, 11:30 AM to 1:00 PM

Location: Arie Crown Theater

CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).

Advanced Disease

Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Discussion Session (Board #4)

J Clin Oncol 37, 2019 (suppl; abstr 3512)

Author(s): Eric Xueyu Chen, Derek J. Jonker, Jonathan M. Loree, Hagen F. Kennecke, Scott R. Berry, Felix Couture, Chaudhary E. Ahmad, John R. Goffin, Petr Kavan, Mohammed Harb, Bruce Colwell, Setareh Samimi, Benoit Samson, Tahir Abbas, Nathalie Aucoin, Francine Aubin, Sheryl L. Koski, Alice Chia-chi Wei, Dongsheng Tu, Christopher J. O'Callaghan; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada; BC Cancer, Vancouver, BC, Canada; Virginia Mason Hospital and Medical Center, Seattle, WA; Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada; Newfoundland Cancer, St John's, NL, Canada; Juravinski Cancer Centre, Burlington, ON, Canada; McGill University, Montreal, QC, Canada; Moncton Hospital, Moncton, NB, Canada; Nova Scotia Cancer Center, Halifax, NS, Canada; University of Montreal Sacre Coeur Hospital, Montreal, QC, Canada; Hopital Charles-LeMoyne, Quebec, QC, Canada; Saskatoon Cancer Centre, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada; Hôpital Cité de la Santé de Laval, Laval, QC, Canada; Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada; Cross Cancer Institute, Edmonton, AB, Canada; University of Toronto, Toronto, ON, Canada; Queen's University, Canadian Cancer Trials Group, Kingston, ON, Canada

Abstract Disclosures


Background: Targeting both PD-L1 and CTLA-4 may be synergistic immunotherapy approaches. CO.26 evaluated if dual inhibition leads to improved pt survival vs BSC alone in rmCRC. Methods: rmCRC pts were randomized 2:1 to D+T vs BSC. Treatment consisted of D (1500 mg) D1 q 28 days and T (75 mg) D1 for first 4 cycles, and supportive measures. Primary endpoint was overall survival (OS). Two-sided p < 0.10 was considered statistically significant. Cell-free (cf)DNA sequencing for MSI and TMB used GuardantOMNI panel and baseline plasma. Results: From 08/2016-06/2017, 180 pts were enrolled. Pt characteristics were balanced between arms. At median follow-up of 15.2 months (mos), median OS was 6.6 mos for D+T and 4.1 mos for BSC (p = 0.07; Hazard ratio (HR): 0.72, 90% confidence interval (CI): 0.54 – 0.97). Progression free survival (PFS) was 1.8 mos vs 1.9 mos, respectively (HR 1.01, 90% CI 0.76 – 1.34). Disease control rate (DCR) was 22.6% for D+T and 6.6% for BSC (p = 0.006). cfDNA analysis was successful in 168/169 pts (99.4%). Two pts were MSI-high. In 166 MSS pts, OS HR was 0.66 (p=0.024; 90% CI 0.49-0.89). Excluding the MSI-H cases (TMB of 74.7 and 247.1 mts/Mb), mean TMB was 20.4 ± 16.3 mts/Mb (range: 0.96 – 114.0). In MSS pts, a pre-specified cutpoint of 20 mts/Mb stratified pts into high and low TMB groups but was not predictive for OS , PFS, or DCR (interaction p-values > 0.7). Using a minimum p-value approach, pts with TMB >28 mts/Mb (21% of MSS pts) had the greatest OS benefit (HR 0.34, 90% CI 0.18-0.63) for D+T (interaction p = 0.07). High TMB was associated with a trend in worse prognosis for OS in the BSC arm using both 20 mts/Mb (HR 1.26, 90% CI 0.76-2.12) and 28 mts/Mb (HR 2.59 90% CI 1.46-4.62) cutpoints. Conclusions: D+T significantly prolonged OS in pts with rmCRC. High TMB may select a group of MSS pts who benefit from D+T. Plasma TMB appeared prognostic in the BSC arm. This is the first study showing combined PD-L1 and CTLA-4 inhibition prolongs survival in pts with MSS rmCRC. Updated results based on deaths in more than 90% of pts will be presented. Clinical trial information: NCT02870920

Other Abstracts in this Sub-Category:


1. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3507 First Author: Javier Sastre
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease


2. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3508 First Author: Chiara Cremolini
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease


3. A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3509 First Author: Filippo Pietrantonio
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease